Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway

Wu,Hongwei; Dai,Xiaozhen; Wang,Enren

doi:10.3892/ol.2016.5048

Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway

Authors:
- Hongwei Wu
- Xiaozhen Dai
- Enren Wang
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Biological and Medical Sciences, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Neuromedicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China
Published online on: August 26, 2016 https://doi.org/10.3892/ol.2016.5048
Pages: 3614-3618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Plumbagin is the primary component of the traditional Chinese medicine Baihua Dan, and possesses anti-infection and anticancer effects with the ability to enhance the sensitivity of tumor cells to radiation therapy. The present study aimed to investigate the potential anticancer effect and mechanism of plumbagin on multiple myeloma (MM) cells. Human MM OPM1 cells were treated with plumbagin, and its impact on cell viability, cytotoxicity, apoptosis and caspase‑3 activity was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, lactate dehydrogenase leakage, flow cytometry and colorimetric assays. In addition, the protein expression levels of phosphoinositide 3‑kinase, phosphorylated (p)‑Akt and p‑mammalian target of rapamycin (mTOR) in OPM1 cells were analyzed by western blotting. The results demonstrated that plumbagin treatment inhibited cell viability, increased cell cytotoxicity, activated cell apoptosis and promoted caspase‑3 activity in the OPM1 cells. Furthermore, pretreatment of plumbagin significantly suppressed PI3K, p‑Akt and p‑mTOR protein expression levels in the OPM1 cells. In conclusion, the present study indicates that plumbagin inhibits cell proliferation and promotes apoptosis in MM cells through inhibition of PI3K/Akt-mTOR expression.

View Figures

View References

1	Liu N, Zhou H, Yang G, Geng C, Jian Y, Guo H and Chen W: Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncol Lett. 9:930–936. 2015.PubMed/NCBI
2	Tan E, Weiss BM, Mena E, Korde N, Choyke PL and Landgren O: Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma. 52:1630–1640. 2011. View Article : Google Scholar : PubMed/NCBI
3	Wang F, Zhang W, Guo L, Bao W, Jin N, Liu R, Liu P, Wang Y, Guo Q and Chen B: Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci. 105:1063–1070. 2014. View Article : Google Scholar : PubMed/NCBI
4	Deng M, Wang J, Chen Y, Zhang L and Liu D: Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Anticancer Drugs. 26:422–427. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD and Kwiatkowski DJ: PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 117:730–738. 2007. View Article : Google Scholar : PubMed/NCBI
6	Padhye S, Dandawate P, Yusufi M, Ahmad A and Sarkar FH: Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 32:1131–1158. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wang T, Wu F, Jin Z, Zhai Z, Wang Y, Tu B, Yan W and Tang T: Plumbagin inhibits LPS-induced inflammation through the inactivation of the nuclear factor-kappa B and mitogen activated protein kinase signaling pathways in RAW 264.7 cells. Food Chem Toxicol. 64:177–183. 2014. View Article : Google Scholar : PubMed/NCBI
8	Inbaraj JJ and Chignell CF: Cytotoxic action of juglone and plumbagin: A mechanistic study using HaCaT keratinocytes. Chem Res Toxicol. 17:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
9	Saowakon N, Lorsuwannarat N, Changklungmoa N, Wanichanon C and Sobhon P: Paramphistomum cervi: The in vitro effect of plumbagin on motility, survival and tegument structure. Exp Parasitol. 133:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
10	Shieh JM, Chiang TA, Chang WT, Chao CH, Lee YC, Huang GY, Shih YX and Shih YW: Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem. 335:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
11	Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He ZX, Zhang X, Wang D, Yang YX, Yang T, et al: Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. Drug Des Devel Ther. 9:537–560. 2015.PubMed/NCBI
12	Troeltzsch M, Oduncu F, Mayr D, Ehrenfeld M, Pautke C and Otto S: Root resorption caused by jaw infiltration of multiple myeloma: Report of a case and literature review. J Endod. 40:1260–1264. 2014. View Article : Google Scholar : PubMed/NCBI
13	Que W, Li S and Chen J: NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells. Mol Med Rep. 7:1641–1645. 2013.PubMed/NCBI
14	Nakazato T, Sagawa M and Kizaki M: Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1. Int J Oncol. 44:1131–1138. 2014.PubMed/NCBI
15	Ono T, Ota A, Ito K, Nakaoka T, Karnan S, Konishi H, Furuhashi A, Hayashi T, Yamada Y, Hosokawa Y and Kazaoka Y: Plumbagin suppresses tumor cell growth in oral squamous cell carcinoma cell lines. Oral Dis. 21:501–511. 2015. View Article : Google Scholar : PubMed/NCBI
16	Eldhose B, Gunawan M, Rahman M, Latha MS and Notario V: Plumbagin reduces human colon cancer cell survival by inducing cell cycle arrest and mitochondria-mediated apoptosis. Int J Oncol. 45:1913–1920. 2014.PubMed/NCBI
17	Dandawate P, Ahmad A, Deshpande J, Swamy KV, Khan EM, Khetmalas M, Padhye S and Sarkar F: Anticancer phytochemical analogs 37: Synthesis, characterization, molecular docking and cytotoxicity of novel plumbagin hydrazones against breast cancer cells. Bioorg Med Chem Lett. 24:2900–2904. 2014. View Article : Google Scholar : PubMed/NCBI
18	Fuchs O: Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 13:16–34. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li YC, He SM, He ZX, Li M, Yang Y, Pang JX, Zhang X, Chow K, Zhou Q, Duan W, et al: Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 344:239–259. 2014. View Article : Google Scholar : PubMed/NCBI
20	Koldehoff M, Beelen DW and Elmaagacli AH: Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells. Cancer Gene Ther. 21:275–282. 2014. View Article : Google Scholar : PubMed/NCBI
21	Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, et al: Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 16:1617–1629. 2015. View Article : Google Scholar : PubMed/NCBI
22	Yang Y, Zhou X, Xiao M, Hong Z, Gong Q, Jiang L and Zhou J: Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. J Huazhong Univ Sci Technolog Med Sci. 30:734–740. 2010. View Article : Google Scholar : PubMed/NCBI
23	Dong M, Yang G, Liu H, Liu X, Lin S, Sun D and Wang Y: Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep. 2:250–254. 2014.PubMed/NCBI
24	Chen X, Yang C, Xu Y, Zhou H, Liu H and Qian W: The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins. Exp Ther Med. 6:299–304. 2013.PubMed/NCBI
25	Jang J, Jeong SJ, Kwon HY, Jung JH, Sohn EJ, Lee HJ, Kim JH and Kim SH, Kim JH and Kim SH: Decursin and doxorubicin are in synergy for the induction of apoptosis via STAT3 and/or mTOR pathways in human multiple myeloma cells. Evid Based Complement Alternat Med. 2013:5063242013. View Article : Google Scholar : PubMed/NCBI
26	Chen MB, Zhang Y, Wei MX, Shen W, Wu XY, Yao C and Lu PH: Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells. Cell Signal. 25:1993–2002. 2013. View Article : Google Scholar : PubMed/NCBI